Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors

British Journal of Dermatology

Volumn 169, Issue 6, 2013, Pages 1310-1313

  Anforth, R ^a,b   Blumetti, T C M P ^a   Clements, A ^b,c   Kefford, R ^b,c,d   Long, G V ^b,c,d   Fernandez Penas P ^a,b  

^a WESTMEAD HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; DABRAFENIB; ETRETIN; RETINOID; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; KERATOLYTIC AGENT; OXIME; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; DESQUAMATION; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; INFORMATION PROCESSING; KERATOSIS; MALE; METASTATIC MELANOMA; MUCOCUTANEOUS DRYNESS; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; SKIN CARCINOMA; VERRUCAL KERATOSIS; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS;

ACITRETIN; AGED; ANTICARCINOGENIC AGENTS; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; HUMANS; IMIDAZOLES; INDOLES; KERATOLYTIC AGENTS; KERATOSIS; MALE; MELANOMA; MIDDLE AGED; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84889064077     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12519     Document Type: Article

References (26)

1. Davies H, Bignell GR, Cox C, et al,. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
2. Chapman PB, Hauschild A, Robert C, et al,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
3. Anforth RM, Blumetti TC, Kefford RF, et al,. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012; 167: 1153-60.
4. Anforth R, Fernandez-Penas P, Long GV,. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013; 14: e11-18.
5. Falchook GS, Long GV, Kurzrock R, et al,. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1dose-escalation trial. Lancet 2012; 379: 1893-901.
6. Chapman PB, Hauschild A, Robert C, et al,. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 2012; 30 (Suppl.): abstr. 8502.
7. Flaherty KT, Puzanov I, Kim KB, et al,. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
8. Sosman JA, Kim KB, Schuchter L, et al,. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
9. Kefford R, Arkenau H, Brown MP, et al,. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010; 28 (Suppl.): abstr. 8503.
10. Shuttleworth D, Marks R, Griffin PJ, Salaman JR,. Treatment of cutaneous neoplasia with etretinate in renal transplant recipients. Q J Med 1988; 68: 717-25.
11. De Graaf YG, Euvrard S, BouwesBavinck JN,. Systemic and topical retinoids in the management of skin cancer in organ transplant recipients. Dermatol Surg 2004; 30: 656-61.
12. Harwood CA, Leedham-Green M, Leigh IM, Proby CM,. Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol 2005; 141: 456-64.
13. Anforth R, Cristina T, Blumetti MP, et al,. Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib. J Clin Oncol 2012; 30: 165-7.
14. Oberholzer PA, Kee D, Dziunycz P, et al,. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012; 30: 316-21.
15. Su F, Viros A, Milagre C, et al,. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012; 366: 207-15.
16. Heidorn SJ, Milagre C, Whittaker S, et al,. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010; 140: 209-21.
17. Hatzivassiliou G, Song K, Yen I, et al,. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431-5.
18. Chu EY, Wanat KA, Miller CJ, et al,. Diverse cutaneous side effects associated with BRAF inhibitor therapy: aclinicopathologic study. J Am Acad Dermatol 2012; 67: 1265-72.
19. Anforth R, Tembe V, Blumetti T, Fernandez-Penas P,. Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking BRAF inhibitors. Pigment Cell Melanoma Res 2012; 25: 569-72.
20. Ezra N, Hamid O, Behroozan D,. Eruptive squamous cell carcinomas associated with BRAF-inhibitor therapy in a patient with metastatic melanoma. Dermatol Surg 2012; 38: 1086-90.
21. Huang V, Hepper D, Anadkat M, Cornelius L,. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol 2012; 148: 628-33.
22. Marquez C, Bair SM, Smithberger E, et al,. Systemic retinoids for chemoprevention of non-melanoma skin cancer in high-risk patients. J Drugs Dermatol 2010; 9: 753-8.
23. Wright TI, Spencer JM, Flowers FP,. Chemoprevention of nonmelanoma skin cancer. J Am Acad Dermatol 2006; 54: 933-46, quiz 947-50.
24. Cheepala SB, Yin W, Syed Z, et al,. Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. Mol Cancer 2009; 8: 27.
25. Gollinick H, Dummler U,. Retinoids. Clin Dermatol 1997; 15: 799-810.
26. Ormerod AD, Campalani E, Goodfield MJ,. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. Br J Dermatol 2010; 162: 952-63.